Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Company Details
- Employees
- 168
- Founded
- -
- Address
- 201 Brookline Ave,
- Phone
- (857) 320-4900
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tangotx.com
- HQ
- Boston, Massachusetts
Tango Therapeutics Questions
Tango Therapeutics's helpline number is (857) 320-4900
Tango Therapeutics's website is tangotx.com
Tango Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tango-therapeutics
Tango Therapeutics has
168 employees.
View email and phone details for 168
employees at Tango Therapeutics.
Tango Therapeutics's industry is
Biotechnology Research
Tango Therapeutics's top competitors are
Relay Therapeutics,
Verve Therapeutics,
C4 Therapeutics, Inc.,
Tessera Therapeutics,
Alnylam Pharmaceuticals,
Kymera Therapeutics,
Foghorn Therapeutics Inc.,
Sarepta Therapeutics,
Beam Therapeutics,
Vertex Pharmaceuticals.
Tango Therapeutics's categories are Biotechnology Research
Tango Therapeutics's founding year is 2017
